Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Overdiagnosis and overtreatment of early detected prostate cancer.

Bangma CH, Roemeling S, Schröder FH.

World J Urol. 2007 Mar;25(1):3-9. Epub 2007 Feb 14. Review.

2.

Cancer overdiagnosis and overtreatment.

Klotz L.

Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa. Review.

PMID:
22472510
3.

Defining and predicting indolent and low risk prostate cancer.

Bangma CH, Roobol MJ.

Crit Rev Oncol Hematol. 2012 Aug;83(2):235-41. doi: 10.1016/j.critrevonc.2011.10.003. Epub 2011 Oct 26. Review.

PMID:
22033113
4.

Overdiagnosis and overtreatment of prostate cancer.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Review.

5.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
6.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

Barry MJ, Mulley AJ Jr.

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10. No abstract available.

PMID:
19276451
7.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
8.

Prostate cancer overdiagnosis and overtreatment.

Klotz L.

Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a. Review.

PMID:
23609043
9.

Active surveillance for prostate cancer: a review.

Klotz L.

Arch Esp Urol. 2011 Oct;64(8):806-14. Review. English, Spanish.

PMID:
22052761
10.

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.

11.

Screening, early detection, and treatment of prostate cancer: a European view.

Schröder FH.

Urology. 1995 Sep;46(3 Suppl A):62-70. Review.

PMID:
7653022
12.

Active surveillance: pitfalls to consider.

Ercole B, Parekh DJ.

Arch Esp Urol. 2011 Oct;64(8):695-702. Review. English, Spanish.

PMID:
22052752
13.

Predictive models in diagnosing indolent cancer.

Bangma CH, Roobol MJ, Steyerberg EW.

Cancer. 2009 Jul 1;115(13 Suppl):3100-6. doi: 10.1002/cncr.24347. Review.

14.

Active surveillance for prostate cancer: progress and promise.

Cooperberg MR, Carroll PR, Klotz L.

J Clin Oncol. 2011 Sep 20;29(27):3669-76. doi: 10.1200/JCO.2011.34.9738. Epub 2011 Aug 8. Review.

16.

[Treatment of localized prostate cancer having a good prognosis may cause more harm than benefit].

Ruutu M, Rannikko A, Malmi H, Vasarainen H, Mikkola A.

Duodecim. 2009;125(14):1516-23. Finnish.

PMID:
19711574
17.

Screening for prostate cancer: early detection or overdetection?

Vickers AJ, Roobol MJ, Lilja H.

Annu Rev Med. 2012;63:161-70. doi: 10.1146/annurev-med-050710-134421. Epub 2011 Nov 3. Review.

18.

Active surveillance for localized prostate cancer--current practices and recommendations.

Wu JN, Dall'Era MA.

ScientificWorldJournal. 2010 Dec 14;10:2352-61. doi: 10.1100/tsw.2010.227.

19.

Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer.

Buethe DD, Pow-Sang J.

J Natl Compr Canc Netw. 2012 Sep;10(9):1101-10. Review.

PMID:
22956809
20.

Early detection of prostate cancer. What do we tell our patients?

Schröder FH, Erasmus MC.

Can J Urol. 2006 Apr;13 Suppl 2:37-42.

PMID:
16672127

Supplemental Content

Support Center